HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HU-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HU-6 overview
HU-6 is under development for the treatment of non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease (NAFLD), severe hypertriglyceridemia (SHTG) and heart failure with preserved ejection fraction (HFpEF). It is administered through oral route. It acts by targeting adenine nucleotide translocase (ANT).
It was also under development for the treatment of obesity and type 2 diabetes
Rivus Pharmaceuticals overview
Rivus Pharmaceuticals is a developer of controlled metabolic accelerators that providing patients with oral small molecule therapeutics which address the underlying metabolic risk factors. The company is headquartered in Charlottesville, Virginia, the US.
For a complete picture of HU-6’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
